"With the many innovations and advances in rheumatology, it is exciting to be a part of the development of these new therapies for patients," says Dr. Maricor Docena, Medical Director at Medpace. In this new video, Dr. Docena shares how Medpace's cross-therapeutic collaboration across immune-mediated inflammatory diseases provides the necessary medical expertise to optimize your trial design while ensuring expedited timelines. If you have an upcoming project that needs seamless execution, contact our #rheumatology experts: https://lnkd.in/gAxJq6Vu
Medpace’s Post
More Relevant Posts
-
Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement. More from our August print book: https://ow.ly/XjbV50PG6TY
To view or add a comment, sign in
-
Serial Entrepreneur. Commercialization and distribution of medical diagnostics, treatments, imaging, biologics, as well as specialized SaaS in both medical and legal industries.
This is a very good synopsis on the mismatch between the basis for the proposed LCD policies on CAMPS and what this would yield in terms of patient and financial outcomes. Clinical efficacy data and outcomes can drive policy that will ultimately control costs if cognizant parameters are established.
Read the open letter by William Tettelbach, Martha Kelso, and David Armstrong - A review of the proposed draft CAMPs LCDs compared to evidence-based medicine: a letter to the MACs for consideration. Access it here: https://lnkd.in/eecFqF3u We encourage replies and will publish any responses we receive as commentary pieces in future issues of JWC. Please contact jwc@markallengroup.com for further details. 📩 William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP Martha R Kelso, RN, CHWS, HBOT David Armstrong
A review of the proposed draft CAMPs LCDs compared to evidence-based medicine: a letter to the MACs for consideration | Journal of Wound Care
magonlinelibrary.com
To view or add a comment, sign in
-
The Minze Health platform is a vital tool in the care pathway. 3 Key Insights from the Daily Use of the Diary Pod: 📊 Securing Reimbursement: The Diary Pod supports approvals for 2nd and 3rd-line treatments (Medications, Botox, SNM/SNS, PTNS) by providing real-world and evidence-based automated bladder diary data. 📈 Time Efficiency: Recognized as a "game-changer" by urologists, the Diary Pod ensures complete data collection, minimizing diary-related time and enhancing practice efficiency with quick, auto-calculated result interpretation and seamless EMR integration. 🙋♀️ Patient Compliance: Simplifying the bladder diary process, the Minze Diary Pod improves compliance and satisfaction, crucial for better data, diagnostics, and treatment adherence. Contact Minze Health or Exodus Scientific for a demonstration.
Minze's Diary Pod (Automated Bladder Diary) has already earned recognition from urologists worldwide for its precise data collection and user-friendly interface. This study further confirms the added value of the Diary Pod in both daily clinical practice and research.
CaMiCon Study reveals the benefits of an automated bladder diary versus a traditional pen-and-paper method.
https://minzehealth.com
To view or add a comment, sign in
-
Congratulations to Brien P Cummings and the Healio Clinical Guidance team on the launch of their latest module on #Lupus. Click here for the Overview, Presentation and Diagnosis, Treatment Options, Treatment Guidelines, and more. https://lnkd.in/egkBmnvf
Clinical Guidance on Lupus | Free Clinical Guidance | Healio
healio.com
To view or add a comment, sign in
-
NEW from #ASCAT2023 | STArT trial: #arginine in the treatment of #SCD pain 🎥 Andrew Campbell, MD, Children’s National Medical Center, The George Washington University School of Medicine and Health Sciences, provides insights into the ongoing #SickleCellDisease Treatment with #ArginineTherapy (START) trial (NCT04839354)🩸 This trial investigates the efficacy of #arginine in mitigating #pain crises, thereby reducing hospitalization durations. Dr Campbell also outlines ongoing trials assessing the efficacy of #citrulline, a #precursor to arginine, with the same primary endpoint💡 Give it a watch to learn more 👉 https://lnkd.in/eiUyx6EY #HemOnc #sicklecelldisease #sicklecell #sicklecellawareness #thalassemia Academy For Sickle Cell & Thalassaemia
STArT trial: arginine in the treatment of SCD pain | VJHemOnc
https://www.vjhemonc.com
To view or add a comment, sign in
-
🚀 Revolutionizing the future of medicine 🚀 Citeline Connect partner HealthMatch doesn't just talk about change; they drive it. With 3.6M+ patient matches across 300+ conditions, they're fast-tracking the path to clinical trial success by: 🎯 Connecting patients to tomorrow's treatments today through newsletter, ad, email and web campaigns. 🌍 Serving the US, Australia, & New Zealand in multiple areas, including Autoimmune, Cardiology, Central Nervous System (CNS), Dermatology, Gastroenterology, Infectious Diseases and Vaccines, Metabolism and Endocrinology, Psychiatry, Respiratory, Rheumatology, Substance Abuse, and Women's Health. Discover how partners like HealthMatch can help skyrocket your company's recruitment: https://ow.ly/XNiz50PGrGk. Dive deeper into HealthMatch: https://ow.ly/1wCl50PGrGj 🌐 #ClinicalTrials #MedicalResearch #PatientRecruitment
Patient Recruitment Collective
pages.pharmaintelligence.informa.com
To view or add a comment, sign in
-
#CaseReport of "Was Amputating the Foot the Best Therapeutic Option? Double Focal Compression Bandaging Technique" by Carlos Sánchez Fernández de la Vega is published in Acta Scientific Clinical Case Reports Journal. Abstract: This clinical case describes a complication in the removal of osteosynthesis material, implanted for a bimalleolar fracture of the right ankle. The importance of the case lies, in the therapeutic options indicated by the trauma and infectious diseases services, while hospitalised: Amputating his foot was the safest and best option, and although he initially accepted it, he later refused to go along with it, taking the risk himself. He decided to continue with the pharmacological treatment, as well as other therapeutic measures. Months later, the patient started another treatment at our clinic. He was treated with a compression bandage and focused pressure on the wound bed. A technique that applies pressure to the wound, using only bandages and gauze. The result was incredibly good. He came in a wheelchair to have his ankle treated, and after compression therapy, he started using crutches, then walking sticks and later he was able to walk on his own. The patient was under our care for 2.5 years, then under the care of his general practitioner and other hospital specialists (traumatologist and internal medicine). During this time, he only came to our office for radiological monitoring, when we ordered it. I have used this case to explain, based on pathophysiology, the clinical improvement in patients with congestive heart failure (NYHA I, II and III), when we applied compression bandages to them. I think physiological secretion of natriuretic peptides is the key. Accepting articles for the next issue by January 20, 2024 Submissions to : casereports@actascientific.com Submission link: https://lnkd.in/gfdmPeg For any queries: Ms. Deepthi(Managing Editor) 📞 ☎Call/Whatsapp: +91-88850-18662 #casereports #clinicalcase #medicines #casereport #OpenAccess #openaccessjournal #onlinepublishing #onlinepublication #actascientific Have a look at the complete paper: https://lnkd.in/gXFTi6YY
To view or add a comment, sign in
-
Felix Perez, CEO Research Director
1moExciting advancements in rheumatology! Dr. Maricor Docena's insights into Medpace's cross-therapeutic collaboration are invaluable for optimizing trial design and timelines.